Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report

Epoprostenol is a prostacyclin (prostaglandin I2) analog that causes vasodilation and inhibits platelet aggregation and is used in the management of severe pulmonary arterial hypertension (PAH). We herein report a patient with PAH who developed pancreatic enlargement after the initiation of therapy...

Full description

Saved in:
Bibliographic Details
Published in:Abdominal imaging 2022-06, Vol.47 (6), p.1948-1953
Main Authors: Someya, Yuko, Koyasu, Sho, Ohnishi, Yasuyuki, Ohno, Tsuyoshi, Shimizu, Hironori, Isoda, Hiroyoshi, Nakamoto, Yuji
Format: Article
Language:English
Subjects:
Case reports
Enlargement
Gastroenterology
Hepatology
Hypertension
Imaging
Intravenous administration
Medicine
Medicine & Public Health
Pancreas
Pancreatitis
Platelet aggregation
Prostacyclin
Pulmonary hypertension
Radiology
Side effects
Special Section: JSAR
Therapy
Thyroid
Vasodilation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epoprostenol is a prostacyclin (prostaglandin I2) analog that causes vasodilation and inhibits platelet aggregation and is used in the management of severe pulmonary arterial hypertension (PAH). We herein report a patient with PAH who developed pancreatic enlargement after the initiation of therapy including epoprostenol. Although it is well known that thyroid enlargement occurs in patients with PAH receiving epoprostenol therapy, the pancreatic findings associated with epoprostenol therapy have not been well described. Although the size of the pancreas was clearly increased, there was no blood data or symptoms suggestive of abnormal pancreatic function and pancreatitis, and the patient’s abdominal complaints improved quickly, despite the continuation of epoprostenol therapy. Eleven months after the start of continuous intravenous epoprostenol infusion therapy, the pancreatic enlargement was still evident on imaging, but there were no abdominal symptoms or elevated pancreatic enzymes. This case highlights the fact that epoprostenol therapy may cause pancreatic changes that mimic acute or autoimmune pancreatitis.
ISSN:2366-0058
2366-004X
2366-0058
DOI:10.1007/s00261-022-03458-9